Sugi Predict

Sugi Predict / Compounds / SCHEMBL1709936

SCHEMBL1709936

SCHEMBL1709936

CC1(N)CCN(C(=O)OCc2ccccc2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.59
▸ KMT2A Q03164 2/20 0.59
▸ NPSR1 Q6W5P4 2/20 0.59
▸ SMN1; SMN2 Q16637 4/20 0.59
▸ CYP2C19 P33261 1/20 0.59
▸ NPC1 O15118 2/20 0.58
▸ RAB9A P51151 2/20 0.58
▸ OPRD1 P41143 1/20 0.54
▸ OPRK1 P41145 1/20 0.54
▸ KDM1A O60341 1/20 0.51
▸ ALDH1A1 P00352 3/20 0.51
▸ KDM4E B2RXH2 1/20 0.51
▸ MAPT P10636 1/20 0.51
▸ HTT P42858 1/20 0.50
▸ RORC P51449 2/20 0.49
▸ HDAC3 O15379 2/20 0.49
▸ HDAC1 Q13547 2/20 0.49
▸ HDAC2 Q92769 2/20 0.49
▸ HDAC6 Q9UBN7 2/20 0.49
▸ ENPP2 Q13822 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL566838 0.87 MEN1 (0.61) MEN1KMT2ANPSR1SMN1; SMN2CYP2C19
SCHEMBL28474414 0.86 MEN1 (0.59) MEN1KMT2ANPSR1SMN1; SMN2CYP2C19
SCHEMBL31468184 0.86 MEN1 (0.59) MEN1KMT2ANPSR1SMN1; SMN2CYP2C19
SCHEMBL6984069 0.86 MEN1 (0.59) MEN1KMT2ANPSR1SMN1; SMN2CYP2C19
SCHEMBL631455 0.86 MEN1 (0.59) MEN1KMT2ANPSR1SMN1; SMN2CYP2C19
SCHEMBL19766668 0.85 MEN1 (0.55) MEN1KMT2ANPSR1SMN1; SMN2CYP2C19
SCHEMBL27951319 0.85 MEN1 (0.56) MEN1KMT2ANPSR1SMN1; SMN2CYP2C19
SCHEMBL56293 0.84 OPRD1 (0.58) MEN1KMT2ANPSR1SMN1; SMN2CYP2C19
SCHEMBL13690026 0.84 MEN1 (0.58) MEN1KMT2ANPSR1SMN1; SMN2CYP2C19
SCHEMBL29266964 0.84 MEN1 (0.58) MEN1KMT2ANPSR1SMN1; SMN2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260042759-A1 INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) 2026-02-12 — — US disclosed
US-12466823-B2 Inhibitor containing bicyclic derivative, preparation method therefor and use thereof SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2025-11-11 — — US disclosed
EP-3971187-B1 INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) 2025-05-07 — — EP disclosed
EP-3468953-B1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GLAXOSMITHKLINE IP DEV LTD (GB) 2024-05-22 — — EP disclosed
CN-116444515-A Di-ring derivative-containing inhibitor, preparation method and application thereof 上海翰森生物医药科技有限公司 2023-07-18 — — CN disclosed
CN-115974897-A Bicyclic derivative-containing inhibitor, preparation method and application thereof 上海翰森生物医药科技有限公司 2023-04-18 — — CN disclosed
CN-112368283-B Bicyclic derivative-containing inhibitor, preparation method and application thereof 上海翰森生物医药科技有限公司 2023-02-17 — — CN disclosed
US-20220259201-A1 INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2022-08-18 — — US disclosed
CN-109563043-B Substituted pyridines as inhibitors of DNMT1 葛兰素史密斯克莱知识产权发展有限公司 2022-05-31 — — CN disclosed
EP-3971187-A1 INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2022-03-23 — — EP disclosed
EP-0723545-B1 QUINOLIZINONE TYPE COMPOUNDS ABBOTT LAB (US) 2002-05-08 — — EP disclosed
CN-1053188-C Quinolizinone type compounds ABBOTT LAB (US) 2000-06-07 — — CN disclosed
EP-0871628-A1 QUINOLIZINONE TYPE COMPOUNDS Abbott Laboratories (US) 1998-10-21 — — EP disclosed
US-5726182-A TREATMENT OF BACTERIAL INFECTIONS ABBOTT LABORATORIES (US) 1998-03-10 — — US disclosed
US-5599816-A BACTERICIDE ABBOTT LABORATORIES (US) 1997-02-04 — — US disclosed
WO-1996039407-A1 QUINOLIZINONE TYPE COMPOUNDS ABBOTT LABORATORIES (US) 1996-12-12 — — WO disclosed
CN-1137273-A Quinolizinone type compounds ABBOTT LAB (US) 1996-12-04 — — CN disclosed
US-5580872-A ADMINISTERING IN THE TREATMENT OF BACTERIAL INFECTIONS ABBOTT LABORATORIES (US) 1996-12-03 — — US disclosed
EP-0723545-A1 QUINOLIZINONE TYPE COMPOUNDS ABBOTT LABORATORIES (US) 1996-07-31 — — EP disclosed
WO-1995010519-A1 QUINOLIZINONE TYPE COMPOUNDS ABBOTT LABORATORIES (US) 1995-04-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260042759-A1 INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF FAR1, CYP4A11, CYP11B1 MEN1 933/4885KMT2A 2865/4885NPSR1 600/4885
US-20220259201-A1 INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF RET, REL, GOT1 MEN1 662/4885KMT2A 3392/4885NPSR1 3738/4885
US-12466823-B2 Inhibitor containing bicyclic derivative, preparation method therefor and use thereof RET, REL, GOT1 MEN1 662/4885KMT2A 3392/4885NPSR1 3738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.